TXMD 10-Q: SEC filing
TherapeuticsMD
Filed with the SEC on · accession 0001213900-26-119697
TXMD filed a 10-Q (quarterly report) with the SEC on Nov 13, 2026. The quarterly report: unaudited results for the quarter plus management’s comments. The stock moved +2.7% by the first close after the filing.
Summary of the filing
TherapeuticsMD filed its quarterly report on Form 10-Q for the period ended September 30, 2026, reporting routine financial results and disclosures including license agreements with Mayne Pharma and Theramex, and equity transactions with Rubric Capital Management.
Key details
How TXMD stock reacted
Close before
$1.82
Nov 12, 2026
First close after
+2.75%
$1.87
5 trading days
—
Since filing
—
✦ Ask GOAX AI about this filing — what it means for TXMD, what changed since its last filings and what to watch next.
Try it free for 7 days🔔 Want to stay updated on new SEC filings for TXMD?
Click hereFrequently asked questions
What did TXMD file with the SEC on Nov 13, 2026?
TXMD filed a 10-Q (SEC filing). TherapeuticsMD filed its quarterly report on Form 10-Q for the period ended September 30, 2026, reporting routine financial results and disclosures including license agreements with Mayne Pharma and Theramex, and equity transactions with Rubric Capital Management.
How do I read a 10-Q?
The quarterly report: unaudited results for the quarter plus management’s comments. Compare revenue, margins and cash flow with the same quarter last year. Check MD&A for guidance changes and what drove the quarter.
Why are SEC filings important?
Public companies must tell the SEC about anything that can change their value — results, leadership changes, big deals, new shares, bankruptcy. Filings are the official source, often before the news. A 10-Q (quarterly report): The quarterly report: unaudited results for the quarter plus management’s comments.
How did TXMD stock react to this filing?
TXMD closed at $1.82 before the filing and $1.87 on Nov 13, 2026 (+2.75%).
Other TXMD SEC filings
Get alerts when TXMD files with the SEC, plus live charts, key levels and news for 13,000+ stocks.
Try SEPT free for 7 days